文献速递胸部肿瘤

胸膜上皮样间皮瘤:诊断与患者管理的新见解

Update on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management.
PubMed 文献 · J Thorac Oncol · 2026-04-08

本文由IASLC间皮瘤小组委员会综述2021年WHO分类更新,强调上皮样亚型中实性成分或细胞多形性与预后不良相关,推荐两级分级系统,并讨论BAP1、MTAP、NF2及融合基因等诊断与预后标志物及采样方式优化诊断准确性。

要点

  • 上皮样间皮瘤中实性成分或细胞多形性提示预后较差,接近肉瘤样型。
  • 推荐对上皮样间皮瘤采用两级分级系统(低级别与高级别)。
  • BAP1、MTAP、NF2及融合基因等标志物有助于诊断、预后及新兴治疗策略应用。

核心结论

  • 2021年WHO分类强调上皮样间皮瘤的亚型模式和细胞学特征对临床诊断与患者管理的重要性。

研究设计与样本

  • 国际肺癌研究协会罕见肿瘤组间皮瘤小组委员会综述,概述诊断与管理的新要素。

主要发现

  • 上皮样亚型中出现实性成分或细胞多形性特征与更差预后相关,接近肉瘤样间皮瘤。
  • 黏液样间质丰富且实性成分低于50%的病例与生存改善相关。

关键数值与推荐

  • 推荐对上皮样间皮瘤采用两级分级系统(低级别与高级别)。
  • BAP1、甲基硫代腺苷磷酸化酶、NF2及融合基因等标志物与诊断、预后及新兴治疗策略相关。

临床怎么用

  • 临床应关注上皮样间皮瘤的实性成分比例及细胞多形性以评估预后。
  • 采用两级分级系统对上皮样间皮瘤进行风险分层。

局限性

  • 表观遗传学、DNA甲基化及生物标志物在区分间皮瘤与反应性间皮增生及其他肿瘤模拟病变方面存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse mesothelioma is typically diagnosed through histopathologic evaluation. Recent advances in therapeutic strategies have heightened the importance of accurate diagnosis and subtyping. In addition to the three well-established histologic subtypes of mesothelioma (epithelioid, biphasic, and sarcomatoid), the 2021 WHO classification of diffuse pleural mesothelioma emphasizes the importance of subtyping patterns and cytologic features to improve clinical diagnosis and patient management. Notably, the presence of a solid component or pleomorphic cytologic features observed within the epithelioid subtype is associated with a worse prognosis, approaching that of sarcomatoid mesothelioma. Conversely, cases with abundant myxoid stroma and a solid component comprising less than 50% are associated with improved survival. In addition, a two-tiered grading system (low versus high grade) is now recommended for epithelioid mesothelioma. On behalf of the International Association for the Study of Lung Cancer Mesothelioma Sub-Committee of the Rare Tumor Group, we here outline new, essential elements to assist clinicians in optimizing the management of patients with mesothelioma. This includes practical questions on immunohistochemical and molecular markers BAP1, methylthioadenosine phosphorylase, NF2, and fusion genes that are relevant to the diagnosis, prognosis, and application of emerging therapeutic strategies in diffuse pleural mesothelioma. This discussion also addresses frequently asked questions by clinicians regarding sampling modalities aimed at optimizing diagnostic accuracy. The impact of epigenetics, DNA methylation, and biomarker discovery is highlighted, with an emphasis on its limitations in distinguishing mesothelioma from reactive mesothelial proliferations and other neoplastic mimics. The emerging role of artificial intelligence in subtyping, grading, and prediction of biomarkers for genomic subtyping is also discussed.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Sallé FG, Beasley MB, Brcic L, et al. Update on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management. J Thorac Oncol. 2026. PMID: 41962769. doi:10.1016/j.jtho.2026.103720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。